SSAT1 LIQUID BIOPSY ASSAY BioMark Diagnostics

Liquid biopsy for the active detection of enzymes with elevated levels of cancers.

early stage cancer detection - BioMark Diagnostics we believe cancer can be cured
early stage cancer detection - BioMark Diagnostics we believe cancer can be cured

Assay

LIQUID BIOPSY SSAT1 ASSAY

BioMark’s initial liquid biopsy assay detects SSAT1 using an FDA approved drug. SSAT1 is an enzyme with elevated levels in numerous cancers. The assay targets a well researched and understood metabolic pathway. BioMark of a few unique companies using safe therapeutic agents for diagnostic indication. As a non-invasive cost effective red alert tool, it is valuable to physicians around the world. It is a valuable tool for early stage cancer detection.
 
BioMark has completed comprehensive sets of trials. We are now assembling submission packages for Health Canada. Upon approval, physicians can use BioMark for Lung and Breast cancer screening tests. The results will help assess the need for more definitive imaging or other molecular testing.
 
Compelling scientific evidence suggests the liquid biopsy SSAT1 assay can expand to include:
 
  • Glioblastoma (GBM) Cancers
  • Gastrointestinal Cancers
  • Prostate Cancer
  • Head and Neck Cancers
liquid biopsy ssat1 assay biomark diagnostics

Applications

Liquid Biopsy SSAT1 Assay Clinical Applications

  • Test as a “Red Alert”
  • Measure response to treatment
  • Monitor for recurrence for cancer survivors

Clinical Trials

Liquid Biopsy SSAT1 Assay Clinical Trials Completed or "In Progress"

Glioblastoma (GBM): Acetyl amantadine as a diagnostic biomarker for patients with Glioblastoma Multiforme

Principal Investigators: Dr. Don Miller, Dr. Marshall Pitz, CancerCare Manitoba

Status: Open.

7 patients have currently been recruited at CancerCare Manitoba under Drs. M. Pitz and D. Miller. Results on this study will be presented at the upcoming Canadian Cancer Research conference that is scheduled to be held from Nov 8-11, 2021. More patients are being recruited at CancerCare Manitoba and BioMark intends to expand the trial with partners in the USA.

Excretion of Acetylamantadine (AA) by Lung Cancer Patients During a Chemotherapy Regimen

Principal Investigator: Dr. Andrew Maksymiuk, MD, Cancer Care Manitoba
Co-Investigator: Dr. Daniel S. Sitar, Ph.D, University of Manitoba
Co-Investigator: Dr. Paramjit Tappia, Ph.D, Asper Clinical Research Institute

Status: Open. Mid point assessment to establish proof of concept and patients still being enrolled extended ethics approval

Spermidine/spermine N-acetyltransferase 1 (SSAT 1) Gene Expression in Human Cancer

Principal Investigator: Dr. Andrew Maksymiuk, MD, Cancer Care Manitoba

Status: Open.

Urinary Excretion of Acetylamantadine by Cancer Patients

Principal Investigator: Dr. Andrew Maksymiuk, MD, Cancer Care Manitoba

Status: Open. In the process of final submission to Health Canada

Urinary Excretion of Acetylamantadine by Cancer Patients in Bangladesh

Principal Investigator: Prof. (Dr.) Parveen Shahida Akhtar, Head of the Department, Medical oncology,National Institute of Cancer Research and Hospital, Dhaka, Bangladesh

Status: Completed.

Food Effects on the Pharmacokinetics of Amantadine

Principal Investigator: Prof. Zeneng Cheng, Hunan Tiger-xiangya Drug Evaluation center, China

Status: Completed.

Urinary Excretion of Acetylamantadine by Normal Healthy Volunteers

Principal Investigator: Dr. Bram Ramjiawan, Ph. D, St. Boniface Hospital and Research Centre

Status: Completed.

Sign up for the latest Biomark news

No paperwork, no hassle. We keep things digital, easy and regular.

*Zero Spam Policy. You will need to confirm your email address to receive our news to your inbox.

early stage cancer detection - BioMark Diagnostics we believe cancer can be cured
early stage cancer detection - BioMark Diagnostics we believe cancer can be cured

© 2021 BioMark Diagnostics Inc. All Rights Reserved. BioMark’s mission is to provide universal access to a new paradigm in cancer diagnostics using metabolomics.